Ratings Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
3.9 ^USD	-8.88%		-0.51%	+93.07%

Apr. 12	Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology	CI
Apr. 11	Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 65% by 2026.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The group shows a rather high level of debt in proportion to its EBITDA.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last few months, analysts have been revising downwards their earnings forecast.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
AQUESTIVE THERAPEUTICS, INC.	+93.07%	353M	D+
ELI LILLY AND COMPANY	+25.61%	660B	C+
NOVO NORDISK A/S	+24.31%	562B	B
JOHNSON & JOHNSON	-5.24%	358B	C+
MERCK & CO., INC.	+16.49%	322B	B-
ABBVIE INC.	+8.28%	297B	C+
ASTRAZENECA PLC	+12.36%	219B	B+
ROCHE HOLDING AG	-9.78%	196B	A+
NOVARTIS AG	+6.52%	199B	B-
PFIZER, INC.	-8.75%	149B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes